Ferdinando Mannello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1491259/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Current Issues, Challenges, and Future Perspectives in Clinical Laboratory Medicine. Journal of Clinical Medicine, 2022, 11, 634.	1.0	2
2	Do Circulating Histones Represent the Missing Link among COVID-19 Infection and Multiorgan Injuries, Microvascular Coagulopathy and Systemic Hyperinflammation?. Journal of Clinical Medicine, 2022, 11, 1800.	1.0	8
3	Reasoned therapeutic protocol in outpatients with COVID-19. International Angiology, 2021, 40, 170-175.	0.4	1
4	Recent Updates and Advances in Winiwarter-Buerger Disease (Thromboangiitis Obliterans): Biomolecular Mechanisms, Diagnostics and Clinical Consequences. Diagnostics, 2021, 11, 1736.	1.3	11
5	Why Venous Leg Ulcers Have Difficulty Healing: Overview on Pathophysiology, Clinical Consequences, and Treatment. Journal of Clinical Medicine, 2021, 10, 29.	1.0	105
6	MMP-2 and MMP-9 in Human Peripheral Blood: Optimizing Gelatinase Calibrator for Degradome Research and Discovering a Novel Gelatinolytic Enzyme. Journal of Proteome Research, 2020, 19, 525-536.	1.8	7
7	Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Diseases. Journal of Clinical Medicine, 2020, 9, 3634.	1.0	44
8	Pending questions in venous ulcers management. Report from a Symposium of the World Union of Wound Healing Societies International Congress. Veins and Lymphatics, 2020, 9, .	0.1	1
9	Redox homeostasis as a target for new antimycobacterial agents. International Journal of Antimicrobial Agents, 2020, 56, 106148.	1.1	2
10	Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of Clinical Medicine, 2020, 9, 912.	1.0	27
11	New frontiers for an old drug. Journal of Cardiovascular Pharmacology, 2020, 75, 1.	0.8	2
12	The Imbalance among Oxidative Biomarkers and Antioxidant Defense Systems in Thromboangiitis Obliterans (Winiwarter-Buerger Disease). Journal of Clinical Medicine, 2020, 9, 1036.	1.0	16
13	Outpatient execution of vascular ultrasound diagnostic tests during the COVID-19 pandemic position paper of the Italian Society for Vascular Investigation. Vascular Investigation and Therapy, 2020, 3, 102.	0.3	0
14	Efficacy of a Treatment for Gonarthrosis Based on the Sequential Intra-Articular Injection of Linear and Cross-Linked Hyaluronic Acids. Muscles, Ligaments and Tendons Journal, 2019, 09, 606.	0.1	2
15	The Effect of Compression and Lying Down on Local Matrix Metalloproteinases From the Dependent Leg in Healthy Subjects and Varicose Vein Patients. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2018, 6, 296-297.	0.9	0
16	Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients. Frontiers in Neurology, 2018, 9, 1080.	1.1	17
17	Electronegative LDL induces MMP-9 and TIMP-1 release in monocytes through CD14 activation: Inhibitory effect of glycosaminoglycan sulodexide. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3559-3567.	1.8	19
18	Validation of a Gravitational Model to Study Local Endogenous Biomarkers in Chronic Venous Insufficiency. European Journal of Vascular and Endovascular Surgery, 2018, 56, 865-873.	0.8	5

#	Article	IF	CITATIONS
19	Chronic Venous Disorders: The Dangerous, the Good, and the Diverse. International Journal of Molecular Sciences, 2018, 19, 2544.	1.8	41
20	Sub-Cellular Localization of Metalloproteinases in Megakaryocytes. Cells, 2018, 7, 80.	1.8	13
21	New horizon for breast cancer biomarker discoveries: What might the liquid biopsy of nipple aspirate fluid hold?. Proteomics - Clinical Applications, 2017, 11, 1700060.	0.8	7
22	Chronic Venous Insufficiency: Transforming Growth Factor-Î ² Isoforms and Soluble Endoglin Concentration in Different States of Wound Healing. International Journal of Molecular Sciences, 2017, 18, 2206.	1.8	26
23	Protease Expression Levels in Prostate Cancer Tissue Can Explain Prostate Cancer-Associated Seminal Biomarkers—An Explorative Concept Study. International Journal of Molecular Sciences, 2017, 18, 976.	1.8	14
24	Inflammation and compression: the state of art. Veins and Lymphatics, 2016, 5, .	0.1	3
25	Pharmacologic treatment to improve venous leg ulcer healing. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2016, 4, 371-374.	0.9	19
26	Glutathione Depletion Is Linked with Th2 Polarization in Mice with a Retrovirus-Induced Immunodeficiency Syndrome, Murine AIDS: Role of Proglutathione Molecules as Immunotherapeutics. Journal of Virology, 2016, 90, 7118-7130.	1.5	35
27	Do matrix metalloproteinases represent reliable circulating biomarkers in colorectal cancer?. British Journal of Cancer, 2016, 115, 633-634.	2.9	4
28	Chronic venous disease – Part I: Inflammatory biomarkers in wound healing. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1964-1974.	1.8	41
29	Chronic venous disease – Part II: Proteolytic biomarkers in wound healing. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1900-1908.	1.8	43
30	Breast cyst fluid heparan sulphate is distinctively <i>N</i> â€sulphated depending on apocrine or flattened type. Cell Biochemistry and Function, 2015, 33, 128-133.	1.4	2
31	Aluminum induces inflammatory and proteolytic alterations in human monocytic cell line. Journal of Inorganic Biochemistry, 2015, 152, 190-198.	1.5	5
32	Matrix Metalloproteinase Profiles in Chronic Venous Ulcer Wound Fluid of Inflammatory and Granulating Venous Leg Ulcers. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2015, 3, 119-120.	0.9	6
33	Society for Vascular Surgery and American Venous Forum Guidelines on the management of venous leg ulcers: the point of view of the International Union of Phlebology. International Angiology, 2015, 34, 202-18.	0.4	33
34	Sulodexide Down-Regulates the Release of Cytokines, Chemokines, and Leukocyte Colony Stimulating Factors from Human Macrophages: Role of Glycosaminoglycans in Inflammatory Pathways of Chronic Venous Disease. Current Vascular Pharmacology, 2014, 12, 173-185.	0.8	44
35	Characterization of oversulfated chondroitin sulfate rich in 4,6â€ <i>O</i> àê€disulfated disaccharides in breast cyst fluids collected from human breast gross cysts. Cell Biochemistry and Function, 2014, 32, 344-350.	1.4	3
36	Omics profiles in chronic venous ulcer wound fluid: innovative applications for translational medicine. Expert Review of Molecular Diagnostics, 2014, 14, 737-762.	1.5	43

#	Article	lF	CITATIONS
37	Weight loss surgery improves the metabolic status in an obese rat model but does not affect bladder fibrosis associated with high fat diet feeding. International Journal of Obesity, 2014, 38, 1061-1067.	1.6	6
38	Pathophysiology of chronic venous disease. International Angiology, 2014, 33, 212-21.	0.4	67
39	Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. International Angiology, 2014, 33, 236-42.	0.4	34
40	Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome. BMC Cancer, 2013, 13, 344.	1.1	24
41	Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm. BMC Medicine, 2013, 11, 169.	2.3	42
42	Aluminium and breast cancer: Sources of exposure, tissue measurements and mechanisms of toxicological actions on breast biology. Journal of Inorganic Biochemistry, 2013, 128, 257-261.	1.5	87
43	Aluminium, carbonyls and cytokines in human nipple aspirate fluids: Possible relationship between inflammation, oxidative stress and breast cancer microenvironment. Journal of Inorganic Biochemistry, 2013, 128, 250-256.	1.5	35
44	The Matrix Metalloproteinase Inhibitor Marimastat Promotes Neural Progenitor Cell Differentiation into Neurons by Gelatinase-Independent TIMP-2-Dependent Mechanisms. Stem Cells and Development, 2013, 22, 345-358.	1.1	23
45	Development and use of sulodexide in vascular diseases: implications for treatment. Drug Design, Development and Therapy, 2013, 8, 49.	2.0	93
46	Glycosaminoglycan Sulodexide Inhibition of MMP-9 Gelatinase Secretion and Activity: Possible Pharmacological Role Against Collagen Degradation in Vascular Chronic Diseases. Current Vascular Pharmacology, 2013, 11, 354-365.	0.8	51
47	The MMPs Genes Polymorphisms: Potential Role in Pharmacogenomics and Target Therapy. Journal of Pharmacogenomics & Pharmacoproteomics, 2012, 03, .	0.2	0
48	Deciphering the single-cell omic: innovative application for translational medicine. Expert Review of Proteomics, 2012, 9, 635-648.	1.3	21
49	Nuclear localization of Matrix metalloproteinases. Progress in Histochemistry and Cytochemistry, 2012, 47, 27-58.	5.1	117
50	Single-Cell Analysis: from Innovative Omics to Target Therapy. Journal of Pharmacogenomics & Pharmacoproteomics, 2012, 03, .	0.2	3
51	Differential expression of MMP-2 and MMP-9 activity in megakaryocytes and platelets. Blood, 2011, 118, 6470-6471.	0.6	13
52	Hypoxia and neural stem cells: from invertebrates to brain cancer stem cells. International Journal of Developmental Biology, 2011, 55, 569-581.	0.3	27
53	Aluminium and human breast diseases. Journal of Inorganic Biochemistry, 2011, 105, 1484-1488.	1.5	53
54	Chondroitin sulfate structure is modified in human milk produced by breast affected by invasive carcinoma. Breast, 2011, 20, 586-587.	0.9	5

#	Article	IF	CITATIONS
55	What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?. BMC Medicine, 2011, 9, 95.	2.3	18
56	Analysis of aluminium content and iron homeostasis in nipple aspirate fluids from healthy women and breast cancerâ€affected patients. Journal of Applied Toxicology, 2011, 31, 262-269.	1.4	56
57	Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. American Journal of Translational Research (discontinued), 2011, 3, 149-58.	0.0	36
58	Detection of Superoxide Dismutase-1 in Nipple Aspirate Fluids: A Reactive Oxygen Species—Regulating Enzyme in the Breast Cancer Microenvironment. Clinical Breast Cancer, 2010, 10, 238-245.	1.1	16
59	Iron-binding proteins and C-reactive protein in Nipple Aspirate Fluids: role of Iron-driven inflammation in breast cancer microenvironment?. American Journal of Translational Research (discontinued), 2010, 3, 100-13.	0.0	7
60	Neural stem cells at the crossroads: MMPs may tell the way. International Journal of Developmental Biology, 2009, 53, 1-17.	0.3	39
61	Statins and Breast Cancer: May Matrix Metalloproteinase be the Missing Link. Cancer Investigation, 2009, 27, 466-470.	0.6	25
62	Concentration of aluminium in breast cyst fluids collected from women affected by gross cystic breast disease. Journal of Applied Toxicology, 2009, 29, 1-6.	1.4	40
63	New implications of the proteolytic balance between matrix metalloproteinases and their tissue inhibitors in migraine with and without aura. Clinica Chimica Acta, 2009, 409, 1-3.	0.5	2
64	Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles. Journal of Translational Medicine, 2009, 7, 87.	1.8	14
65	Matrix metalloproteinase polymorphisms and HIV anti-retroviral drugs: new implications of pharmacogenomics in therapeutic approaches. Pharmacogenomics Journal, 2009, 9, 355-357.	0.9	3
66	Protein profile ana lysis of the breast microenvironment to differentiate healthy women from breast cancer patients. Expert Review of Proteomics, 2009, 6, 43-60.	1.3	39
67	Intracrinology of breast microenvironment: hormonal status in nipple aspirate fluid and its relationship to breast cancer. Expert Review of Endocrinology and Metabolism, 2009, 4, 493-505.	1.2	9
68	Protein oxidation in breast microenvironment: Nipple aspirate fluid collected from breast cancer women contains increased protein carbonyl concentration. Cellular Oncology, 2009, 31, 383-92.	1.9	15
69	Protein Oxidation in Breast Microenvironment: Nipple Aspirate Fluid Collected from Breast Cancer Women Contains Increased Protein Carbonyl Concentration. Analytical Cellular Pathology, 2009, 31, 383-392.	0.7	4
70	Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2. Breast Cancer Research and Treatment, 2008, 111, 209-218.	1.1	36
71	Nutrients and nipple aspirate fluid composition: the breast microenvironment regulates protein expression and cancer aetiology. Genes and Nutrition, 2008, 3, 77-85.	1.2	17
72	Blood sampling affects circulating TIMP-1 concentration, a useful biomarker in estimating liver fibrosis stages. Hepatology, 2008, 48, 688-689.	3.6	6

#	Article	IF	CITATIONS
73	Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices. Analytical Biochemistry, 2008, 374, 56-63.	1.1	27
74	Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clinical Biochemistry, 2008, 41, 1466-1473.	0.8	30
75	Increased shedding of soluble fragments of Pâ€eadherin in nipple aspirate fluids from women with breast cancer. Cancer Science, 2008, 99, 2160-2169.	1.7	17
76	uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer. BMC Cancer, 2008, 8, 298.	1.1	5
77	Can mitochondrial DNA mutations in circulating white blood cells and serum be used to detect breast cancer?. Breast, 2008, 17, 540-542.	0.9	16
78	Analysis of the intraductal microenvironment for the early diagnosis of breast cancer: identification of biomarkers in nipple-aspirate fluids. Expert Opinion on Medical Diagnostics, 2008, 2, 1221-1231.	1.6	14
79	From bone marrow to therapeutic applications: different behaviour and genetic/epigenetic stability during mesenchymal stem cell expansion in autologous and foetal bovine sera?. International Journal of Developmental Biology, 2008, 52, 1023-1032.	0.3	104
80	Serum or Plasma Samples?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 611-614.	1.1	84
81	Impact of Blood Sampling on the Circulating Matrix Metalloproteinases 1, 2, 3, 7, 8, and 9. Clinical Chemistry, 2008, 54, 772-773.	1.5	45
82	Erythropoietin and Its Receptor in Breast Cancer: Putting Together the Pieces of the Puzzle. Oncologist, 2008, 13, 761-768.	1.9	10
83	Increased Levels of Erythropoietin in Nipple Aspirate Fluid and in Ductal Cells from Breast Cancer Patients. Analytical Cellular Pathology, 2008, 30, 51-61.	0.7	6
84	Silicate Increases the Release of MMP-9 Forms in Peripheral Blood: Why Gelatin Zymography Differs Significantly in Citrate Plasma and Serum Obtained with or without Clot Activators. Clinical Chemistry, 2007, 53, 1981-1982.	1.5	17
85	Zymographic Analysis and Characterization of MMP-2 and -9 Forms in Human Sound Dentin. Journal of Dental Research, 2007, 86, 436-440.	2.5	260
86	The `never-ending story' of the influence of blood specimen collection methods affecting the concentration, the zymographic profile and the usefulness of matrix metalloproteinases and their tissue inhibitors in multiple sclerosis diagnosis/prognosis: a landmark for limiting the misuse of serum samples. Multiple Sclerosis Journal, 2007, 13, 687-690.	1.4	6
87	Melatonin reduces early changes in intramitochondrial cardiolipin during apoptosis in U937 cell line. Toxicology in Vitro, 2007, 21, 293-301.	1.1	38
88	Acetylcholine induces neurite outgrowth and modulates matrix metalloproteinase 2 and 9. Biochemical and Biophysical Research Communications, 2007, 362, 269-274.	1.0	17
89	The 8-epimer of prostaglandin F2α, a marker of lipid peroxidation and oxidative stress, is decreased in the nipple aspirate fluid of women with breast cancer. International Journal of Cancer, 2007, 120, 1971-1976.	2.3	31
90	Gelatinase concentrations and zymographic profiles in human breast cancer: Matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: The coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. International Journal of Cancer, 2007, 121, 216-218.	2.3	27

#	Article	IF	CITATIONS
91	Concise Review: No Breakthroughs for Human Mesenchymal and Embryonic Stem Cell Culture: Conditioned Medium, Feeder Layer, or Feeder-Free; Medium with Fetal Calf Serum, Human Serum, or Enriched Plasma; Serum-Free, Serum Replacement Nonconditioned Medium, or Ad Hoc Formula? All That Clitters Is Not Gold!. Stem Cells, 2007, 25, 1603-1609.	1.4	272
92	Do nipple aspirate fluid epithelial cells and their morphology predict breast cancer development?. Breast Cancer Research and Treatment, 2007, 102, 125-127.	1.1	12
93	Activation of gelatinolytic/collagenolytic activity in dentin by self-etching adhesives. European Journal of Oral Sciences, 2006, 114, 160-166.	0.7	295
94	Melatonin prevents apoptosis induced by UV-B treatment in U937 cell line. Journal of Pineal Research, 2006, 40, 158-167.	3.4	59
95	Role and Function of Matrix Metalloproteinases in the Differentiation and Biological Characterization of Mesenchymal Stem Cells. Stem Cells, 2006, 24, 475-481.	1.4	126
96	Commentary: Multipotent Mesenchymal Stromal Cell Recruitment, Migration, and Differentiation: What Have Matrix Metalloproteinases Got to Do with It?. Stem Cells, 2006, 24, 1904-1907.	1.4	38
97	Human gross cyst breast disease and cystic fluid: bio-molecular, morphological, and clinical studies. Breast Cancer Research and Treatment, 2006, 97, 115-129.	1.1	41
98	Reactivation of inactivated endogenous proteolytic activities in phosphoric acid-etched dentine by etch-and-rinse adhesives. Biomaterials, 2006, 27, 4470-4476.	5.7	335
99	Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 91-103.	0.8	80
100	Benign Breast Diseases: Classification, Diagnosis, and Management. Oncologist, 2006, 11, 1132-1134.	1.9	10
101	Flow cytometric evaluation ofVibrio parahaemolyticus adhesion inhibition to human epithelial cells. Cytometry Part B - Clinical Cytometry, 2005, 66B, 25-35.	0.7	10
102	Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2005, 10, 19-24.	2.2	127
103	Matrix Metalloproteinase Inhibitors as Anticancer Therapeutics. Current Cancer Drug Targets, 2005, 5, 285-298.	0.8	131
104	Measurements, Zymographic Analysis, and Characterization of Matrix Metalloproteinase-2 and -9 in Healthy Human Umbilical Cord Blood. Clinical Chemistry, 2004, 50, 1715-1717.	1.5	7
105	Evaluation of leukocyte stabilisation in TransFix®-treated blood samples by flow cytometry and transmission electron microscopy. Journal of Immunological Methods, 2004, 295, 67-78.	0.6	49
106	Integrin and cytoskeleton behaviour in human neuroblastoma cells during hyperthermia-related apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2004, 9, 635-648.	2.2	42
107	Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer, 2003, 97, 201-203.	2.0	14
108	HER2 and proliferation of wound-induced breast carcinoma. Lancet, The, 2003, 362, 1503.	6.3	4

#	Article	IF	CITATIONS
109	HER2 and proliferation of wound-induced breast carcinoma. Lancet, The, 2003, 362, 1503-1504.	6.3	3
110	Characterization of metalloproteinase-like activities in barnacle (Balanus amphitrite) nauplii. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2003, 135, 17-24.	0.7	10
111	Zymographic Analyses and Measurement of Matrix Metalloproteinase-2 and -9 in Nipple Aspirate Fluids. Clinical Chemistry, 2003, 49, 1546-1550.	1.5	34
112	Effect of Anticoagulants and Cell Separation Media as Preanalytical Determinants on Zymographic Analysis of Plasma Matrix Metalloproteinases. Clinical Chemistry, 2003, 49, 1956-1957.	1.5	55
113	Effects of Blood Collection Methods on Gelatin Zymography of Matrix Metalloproteinases. Clinical Chemistry, 2003, 49, 339-340.	1.5	54
114	Peritoneal Dialysis and Epithelial-to-Mesenchymal Transition. New England Journal of Medicine, 2003, 348, 2037-2039.	13.9	5
115	Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics?. Breast Cancer Research, 2001, 3, 238.	2.2	33
116	Biochemical properties of metalloproteinases from the hemolymph of the mussel Mytilus galloprovincialis Lam Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2001, 128, 507-515.	0.7	21
117	Prostate cancer screening. Lancet, The, 2001, 357, 1202.	6.3	0
118	Differential distribution of soluble and complexed forms of prostate‐specific antigen in cyst fluids of women with gross cystic breast disease. Journal of Clinical Laboratory Analysis, 2001, 15, 81-86.	0.9	5
119	Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. , 2001, 6, 479-482.		157
120	Biochemical and ultrastructural features of human milk and nipple aspirate fluids. Journal of Clinical Laboratory Analysis, 2000, 14, 330-335.	0.9	33
121	Matrix metalloproteinases expression in HL-60 promyelocytic leukemia cells during apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2000, 5, 165-172.	2.2	15
122	Prostate-Specific Antigen Synthesis and Secretion by Human Placenta: A Physiological Kallikrein Source during Pregnancy1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 317-321.	1.8	26
123	RE: DETECTION OF CIRCULATING PROSTATE SPECIFIC ANTIGEN EXPRESSING PROSTATIC CELLS IN THE BONE MARROW OF RADICAL PROSTATECTOMY PATIENTS BY SENSITIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION. Journal of Urology, 2000, 163, 253-253.	0.2	11
124	Prostate-Specific Antigen Synthesis and Secretion by Human Placenta: A Physiological Kallikrein Source during Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 317-321.	1.8	15
125	Immunoreactivity, Ultrastructural Localization, and Transcript Expression of Prostate-specific Antigen in Human Neuroblastoma Cell Lines. Clinical Chemistry, 1999, 45, 78-84.	1.5	18
126	Molecular Forms and Ultrastructural Localization of Prostate-specific Antigen in Nipple Aspirate Fluids,. Clinical Chemistry, 1999, 45, 2263-2266.	1.5	16

#	Article	IF	CITATIONS
127	Prostate-specific Antigen Expression in Normal Human Bone Marrow Cells. Clinical Chemistry, 1999, 45, 1102-1103.	1.5	4
128	The kidney during hibernation and arousal from hibernation. A natural model of organ preservation during cold ischaemia and reperfusion. Nephrology Dialysis Transplantation, 1999, 14, 1982-1990.	0.4	66
129	Prostateâ€specific antigen found in Type I breast cyst fluids is a secretory product of the apocrine cells lining breast gross cysts. Breast Cancer Research and Treatment, 1999, 57, 157-163.	1.1	12
130	Breast cancer in women with palpable breast cysts. Lancet, The, 1999, 354, 677-678.	6.3	11
131	Immunoreactivity, ultrastructural localization, and transcript expression of prostate-specific antigen in human neuroblastoma cell lines. Clinical Chemistry, 1999, 45, 78-84.	1.5	6
132	Molecular forms and ultrastructural localization of prostate-specific antigen in nipple aspirate fluids. Clinical Chemistry, 1999, 45, 2263-6.	1.5	6
133	Ultrastructural characterization and biochemical profile of human gross cystic breast disease. Breast Cancer Research and Treatment, 1998, 48, 211-219.	1.1	20
134	High Concentrations of Prostate-Specific Antigen in Urine of Women Receiving Oral Contraceptives. Clinical Chemistry, 1998, 44, 181-183.	1.5	14
135	Prostate-specific Antigen Expression in Neuroblastoma Cell Lines. Clinical Chemistry, 1998, 44, 1362-1363.	1.5	3
136	Prostate-specific Antigen Expression in Neoplastic Human Myeloid Cell Lines. Clinical Chemistry, 1998, 44, 1991-1993.	1.5	5
137	Conjugated bile acids in breast cyst fluids: Relationship to cation-related cyst subpopulations. Cancer Letters, 1997, 119, 21-26.	3.2	4
138	Immunoreactive Prostate-Specific Antigen in Pleural Effusions. Clinical Chemistry, 1997, 43, 847-848.	1.5	10
139	Prostate-specific antigen expression in a case of intracystic carcinoma of the breast: characterization of immunoreactive protein and literature surveys. Clinical Chemistry, 1997, 43, 1448-1454.	1.5	20
140	Prostate-Specific Antigen in Ascitic Fluid. Clinical Chemistry, 1997, 43, 1461-1462.	1.5	10
141	Breast gross cystic fluids. I. Protein biochemistry and electrophoretic MAP. Breast, 1997, 6, 325.	0.9	0
142	Breast gross cystic fluids. II. Electron microscopic analysis. Breast, 1997, 6, 326.	0.9	0
143	Prostate-specific antigen expression in a case of intracystic carcinoma of the breast: characterization of immunoreactive protein and literature surveys. Clinical Chemistry, 1997, 43, 1448-54.	1.5	7
144	Lipids status in human breast cyst fluids. Cancer Letters, 1996, 98, 137-143.	3.2	7

#	Article	IF	CITATIONS
145	Immunoreactivity of prostate-specific antigen in plasma and saliva of healthy women. Clinical Chemistry, 1996, 42, 1110-1111.	1.5	18
146	Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. Aids, 1996, 10, 701-710.	1.0	42
147	Quantification of prostate-specific antigen immunoreactivity in human breast cyst fluids. Breast Cancer Research and Treatment, 1996, 38, 247-252.	1.1	28
148	Lipids status in human breast cyst fluids. Cancer Letters, 1996, 98, 137-43.	3.2	4
149	Breast cancer diagnosis by lactate dehydrogenase isozymes in nipple discharge. Cancer, 1995, 76, 152-154.	2.0	12
150	β-Endorphin expression in gross cystic breast disease. Cancer Letters, 1995, 89, 189-193.	3.2	1
151	α1-Antichymotrypsin complexes in human breast cyst fluids. Cancer Letters, 1994, 76, 155-159.	3.2	10
152	Hydrogen peroxide cytotoxicity under conditions of normal or reduced catalase activity in H2O2-sensitive and -resistant Chinese hamster ovary (CHO) cell variants. Toxicology Letters, 1994, 73, 193-199.	0.4	5
153	Goat Immunoglobulin Purification on Phosphocellulose and Deae Affi -Gel Blue. Preparative Biochemistry and Biotechnology, 1994, 24, 1-13.	0.4	8
154	Development and characterization of hydrogen peroxide-resistant chinese hamster ovary cell variants—I. Biochemical Pharmacology, 1993, 45, 2251-2257.	2.0	23
155	Lipid-associated sialic acid levels in human breast cyst fluids. Breast Cancer Research and Treatment, 1992, 24, 167-170.	1.1	8
156	Improved "electrophoretic map" of breast cyst fluid proteins. Cancer Detection and Prevention, 1992, 16, 107-12.	2.1	7
157	Tissue polypeptide specific antigen in human breast cyst fluids. European Journal of Cancer & Clinical Oncology, 1991, 27, S80.	0.9	1
158	Circulating Immune Complexes in Human Breast Cyst Fluids: Relationship with Intracystic Immunoglobulin and Electrolyte Levels. International Journal of Biological Markers, 1991, 6, 122-128.	0.7	3
159	Circulating immune complexes in human breast cyst fluids: relationship with intracystic immunoglobulin and electrolyte levels. International Journal of Biological Markers, 1991, 6, 122-7.	0.7	3
160	Ferritin and transferrin levels in human breast cyst fluids: relationship with intracystic electrolyte concentrations. Clinica Chimica Acta, 1990, 192, 1-7.	0.5	8
161	PCR amplification and silver stain detection of genomic DNA fragments. Trends in Genetics, 1989, 5, 293.	2.9	1
162	Lactate dehydrogenase, isoenzyme patterns and cation levels in human breast gross cyst fluid. Clinica Chimica Acta, 1987, 169, 91-97.	0.5	11

#	Article	IF	CITATIONS
163	Alkaline Phosphatase Expression in Human Chorionic Villi. Pathobiology, 1987, 55, 34-41.	1.9	2
164	Phosphohydrolase analysis in human chorionic villi. Placenta, 1986, 7, 469-470.	0.7	0
165	Hydroxyproline and creatinine levels in normal amniotic fluid. Research in Clinic and Laboratory, 1986, 16, 37-41.	0.3	2
166	α ₁ -Antitrypsin, Transferrin, Alkaline Phosphatase, Phosphohexoseisomerase and γ-Glutamyltransferase in Breast Cyst Fluid. Tumori, 1985, 71, 135-140.	0.6	12
167	Alpha 1-antitrypsin, transferrin, alkaline phosphatase, phosphohexoseisomerase and gamma-glutamyltransferase in breast cyst fluid. Tumori, 1985, 71, 135-40.	0.6	6